EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xintela AB's enterprise value is kr157.94 Mil.
Xintela AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.38 Mil. Therefore, Xintela AB's EV-to-Revenue for today is 418.95.
The historical rank and industry rank for Xintela AB's EV-to-Revenue or its related term are showing as below:
OSTO:XINT'
s EV-to-Revenue Range Over the Past 10 Years
Min: 20.43 Med: 171.14 Max: 550.05
Current: 418.94
During the past 11 years, the highest EV-to-Revenue of Xintela AB was 550.05. The lowest was 20.43. And the median was 171.14.
OSTO:XINT's EV-to-Revenue is ranked worse than 92.08% of 1035
companies
in the Biotechnology industry
Industry Median: 7.54
vs OSTO:XINT: 418.94
As of today (2024-06-21), Xintela AB's stock price is kr0.296.
Xintela AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00. Therefore, Xintela AB's PS Ratio for today is .
Xintela AB EV-to-Revenue Historical Data
The historical data trend for Xintela AB's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xintela AB's EV-to-Revenue
For the Biotechnology subindustry, Xintela AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xintela AB's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xintela AB's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Xintela AB's EV-to-Revenue falls into.
Xintela AB's current Enterprise Value is kr157.94 Mil.
Xintela AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB's share price for today is kr0.296.
Xintela AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Xintela AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:XINT has been successfully added to your 